{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:37:38Z","timestamp":1792255058188,"version":"4.4.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T00:00:00Z","timestamp":1280448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00296-010-1586-z","type":"journal-article","created":{"date-parts":[[2010,7,29]],"date-time":"2010-07-29T09:33:47Z","timestamp":1280396027000},"page":"289-300","source":"Crossref","is-referenced-by-count":39,"title":["Current, new and future treatments of osteoporosis"],"prefix":"10.1007","volume":"31","author":[{"given":"Pooneh","family":"Salari Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagher","family":"Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,30]]},"reference":[{"issue":"2","key":"1586_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.fertnstert.2009.05.049","volume":"92","author":"MS Nanes","year":"2009","unstructured":"Nanes MS, Kallen CB (2009) Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis. Fertil Steril 92(2):403\u2013412","journal-title":"Fertil Steril"},{"issue":"3","key":"1586_CR2","first-page":"RA37","volume":"14","author":"P Salari","year":"2008","unstructured":"Salari P, Rezaie A, Larijani B, Abdollahi M (2008) A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med Sci Monit 14(3):RA37\u2013RA44","journal-title":"Med Sci Monit"},{"key":"1586_CR3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.maturitas.2010.01.002","volume":"65","author":"JC Gallagher","year":"2010","unstructured":"Gallagher JC, Sai AJ (2010) Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas 65:301\u2013307","journal-title":"Maturitas"},{"issue":"5","key":"1586_CR4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/14750708.2.5.787","volume":"2","author":"M Abdollahi","year":"2005","unstructured":"Abdollahi M, Larijani B, Rahimi R, Salari P (2005) Role of oxidative stress in osteoporosis. Therapy 2(5):787\u2013796","journal-title":"Therapy"},{"key":"1586_CR5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1196\/annals.1378.062","volume":"1091","author":"G Yousefzadeh","year":"2006","unstructured":"Yousefzadeh G, Larijani B, Mohammadirad A et al (2006) Determination of oxidative stress status and concentration of TGF-\u03b21 in the blood and saliva of osteoporotic subjects. Ann New York Acad Sci 1091:142\u2013150","journal-title":"Ann New York Acad Sci"},{"key":"1586_CR6","doi-asserted-by":"crossref","unstructured":"Salari P, Asalforoush M, Ameri F, Larijani B, Abdollahi M (2010) The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age 32(2):179\u2013186","DOI":"10.1007\/s11357-009-9122-3"},{"issue":"3","key":"1586_CR7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/187152809788681065","volume":"8","author":"P Salari","year":"2009","unstructured":"Salari P, Abdollahi M (2009) Controversial effects of non-steroidal anti-inflammatory drugs on bone: a review. Inflamm Allergy Drug Targets 8(3):169\u2013175","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"2","key":"1586_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/14750708.5.2.215","volume":"5","author":"P Salari","year":"2008","unstructured":"Salari P, Abdollahi M (2008) Association of hyperhomocysteinemia with osteoporosis: a systematic review. Therapy 5(2):215\u2013222","journal-title":"Therapy"},{"key":"1586_CR9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/ajcn\/87.6.1945","volume":"87","author":"HA Bischoff-Ferrari","year":"2008","unstructured":"Bischoff-Ferrari HA, Rees JR, Grau MV, Barry E, Gui J, Baron JA (2008) Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial. Am J Clin Nutr 87:1945\u20131951","journal-title":"Am J Clin Nutr"},{"key":"1586_CR10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","volume":"354","author":"RD Jackson","year":"2006","unstructured":"Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Eng J Med 354:669\u2013683","journal-title":"N Eng J Med"},{"key":"1586_CR11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/bmj.330.7498.1003","volume":"330","author":"J Porthouse","year":"2005","unstructured":"Porthouse J, Cockayne S, King C et al (2005) Randomised controlled trial of calcium, supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 330:1003","journal-title":"BMJ"},{"key":"1586_CR12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM199009273231305","volume":"323","author":"B Dawson-Hughes","year":"1990","unstructured":"Dawson-Hughes B, Dallal GE, Krall EA, Sadwski L, Sahyoun N, Tannenbaum S (1990) A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Eng J Med 323:878\u2013883","journal-title":"N Eng J Med"},{"key":"1586_CR13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","volume":"370","author":"BM Tang","year":"2007","unstructured":"Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50\u00a0years and older: a meta-analysis. Lancet 370:657\u2013666","journal-title":"Lancet"},{"key":"1586_CR14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1586_CR15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years experience with alendronate for osteoporosis in postmenopausal women. N Eng J Med 350:1189\u20131199","journal-title":"N Eng J Med"},{"key":"1586_CR16","first-page":"CD004523","volume":"1","author":"G Wells","year":"2008","unstructured":"Wells G, Cranney A, Peterson J et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD004523","journal-title":"Cochrane Database Syst Rev"},{"key":"1586_CR17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","volume":"34","author":"B Borah","year":"2004","unstructured":"Borah B, Dufresne TE, Chmielewski PA et al (2004) Risedronate preserves bone architecture in ostmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736\u2013746","journal-title":"Bone"},{"key":"1586_CR18","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"issue":"Suppl 1","key":"1586_CR19","first-page":"S1057","volume":"22","author":"AV Schwartz","year":"2007","unstructured":"Schwartz AV, Bauer DC, Cauley JA et al (2007) Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: the FLEX Trial. J Bone Miner Res 22(Suppl 1):S1057","journal-title":"J Bone Miner Res"},{"key":"1586_CR20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051\u20131056","journal-title":"J Bone Miner Res"},{"key":"1586_CR21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chenut III","year":"2004","unstructured":"Chenut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1586_CR22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023\u20131031","journal-title":"Osteoporos Int"},{"key":"1586_CR23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","volume":"349","author":"MP Whyte","year":"2003","unstructured":"Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteoporosis. N Eng J Med 349:457\u2013463","journal-title":"N Eng J Med"},{"key":"1586_CR24","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Eng J Med 356:1809\u20131822","journal-title":"N Eng J Med"},{"key":"1586_CR25","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) HORIZON recurrent fracture trial: zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Eng J Med 357:1799\u20131809","journal-title":"N Eng J Med"},{"key":"1586_CR26","unstructured":"Zoledronic acid prescribing information. Available at http:\/\/www.pharma.us.novartis.com\/products\/pi\/pdf\/reclast.pdf"},{"key":"1586_CR27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF02555897","volume":"49","author":"S Ljunghall","year":"1991","unstructured":"Ljunghall S, G\u00e4rdsell P, Johnell O et al (1991) Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int 49:17\u201319","journal-title":"Calcif Tissue Int"},{"key":"1586_CR28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF02556148","volume":"48","author":"G Thamsborg","year":"1991","unstructured":"Thamsborg G, Storm TL, Sykulski R, Brinch E, Nielsen HK, Sorensen OH (1991) Effect of different doses of nasal calcitonin on bone mass. Calcif Tissue Int 48:302\u2013307","journal-title":"Calcif Tissue Int"},{"key":"1586_CR29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00310161","volume":"55","author":"NM Nielsen","year":"1994","unstructured":"Nielsen NM, von der Recke P, Hansen MA, Overgaard K, Christiansen C (1994) Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif Tissue Int 55:8\u201311","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 5","key":"1586_CR30","first-page":"S174","volume":"23","author":"SL Silverman","year":"1998","unstructured":"Silverman SL, Chesnut C, Andriano K et al (1998) Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5\u00a0year worldwide data of the PROOF Study. J Bone Miner Res 23(Suppl 5):S174","journal-title":"J Bone Miner Res"},{"key":"1586_CR31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1210\/jc.2002-021988","volume":"88","author":"BM Misof","year":"2003","unstructured":"Misof BM, Roschger P, Cosman F et al (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150\u20131156","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"1586_CR32","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1007\/BF03194365","volume":"7","author":"JY Reginster","year":"1997","unstructured":"Reginster JY, Taquet AN, Fraikin G, Gosset C, Zegels B (1997) Parathyroid hormone in the treatment of involutional osteoporosis: back to the future. Osteoporos Int 7(Suppl 3):S163\u2013S168","journal-title":"Osteoporos Int"},{"key":"1586_CR33","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Eng J Med 344:1434\u20131441","journal-title":"New Eng J Med"},{"key":"1586_CR34","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","volume":"87","author":"JJ Body","year":"2002","unstructured":"Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528\u20134535","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR35","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodson","year":"2005","unstructured":"Hodson AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688\u2013703","journal-title":"Endocr Rev"},{"key":"1586_CR36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP et al (2007) Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326\u2013339","journal-title":"Ann Intern Med"},{"key":"1586_CR37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1210\/jc.2006-1788","volume":"92","author":"DM Antoniucci","year":"2007","unstructured":"Antoniucci DM, Sellmeyer DE, Bilezikian JP et al (2007) Elevations in serum and urinary calcium with parathyroid hormone (1\u201384) with and without alendronate for osteoporosis. J Clin Endocrinol Metab 92:942\u2013947","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized Controlled Trial. JAMA 288:321\u2013333","journal-title":"JAMA"},{"key":"1586_CR39","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00198-006-0187-x","volume":"17","author":"M Kleerekoper","year":"2006","unstructured":"Kleerekoper M (2006) Osteoporosis prevention and therapy: preserving and building strength through bone quality. Osteoporos Int 17:1707\u20131715","journal-title":"Osteoporos Int"},{"key":"1586_CR40","doi-asserted-by":"crossref","first-page":"11312","DOI":"10.1073\/pnas.90.23.11312","volume":"90","author":"N Harada","year":"1993","unstructured":"Harada N, Utsumi T, Takagi Y (1993) Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 90:11312\u201311316","journal-title":"Proc Natl Acad Sci USA"},{"key":"1586_CR41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.2002.17.1.11","volume":"17","author":"BL Riggs","year":"2002","unstructured":"Riggs BL, Melton LJ III (2002) Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11\u201314","journal-title":"J Bone Miner Res"},{"key":"1586_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","volume":"17","author":"S Sarkar","year":"2002","unstructured":"Sarkar S, Mitlak BH, Wong M, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1\u201310","journal-title":"J Bone Miner Res"},{"key":"1586_CR43","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jc.87.8.3609","volume":"87","author":"PD Delmas","year":"2002","unstructured":"Delmas PD, Ensrud KE, Adachi JD et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609\u20133617","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Eng J Med 355:125\u2013137","journal-title":"N Eng J Med"},{"key":"1586_CR45","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E et al (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751\u20131761","journal-title":"J Natl Cancer Inst"},{"key":"1586_CR46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clinthera.2006.02.007","volume":"28","author":"S Epstein","year":"2006","unstructured":"Epstein S (2006) Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Therapeut 28:151\u2013173","journal-title":"Clin Therapeut"},{"key":"1586_CR47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbrc.2009.01.033","volume":"380","author":"M Hirata","year":"2009","unstructured":"Hirata M, Inada M, Matsumoto C et al (2009) A novel carborane analog, BE360, with a carbon-containing polyhedral boron-cluster is a new selective estrogen receptor modulator for bone. Biochem Biophys Res Commun 380:218\u2013222","journal-title":"Biochem Biophys Res Commun"},{"key":"1586_CR48","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"ChristiansenC Silverman","year":"2008","unstructured":"Silverman ChristiansenC, Genant HK et al (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo, and active-controlled clinical trial. J Bone Miner Res 23:1923\u20131934","journal-title":"J Bone Miner Res"},{"key":"1586_CR49","first-page":"S81","volume":"1288","author":"SR Cummings","year":"2008","unstructured":"Cummings SR, Eastell R, Ensrud K et al (2008) The effects of lasofoxifene on fractures, breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 1288:S81","journal-title":"J Bone Miner Res"},{"issue":"S1","key":"1586_CR50","first-page":"S413","volume":"16","author":"S Ronkin","year":"2001","unstructured":"Ronkin S, Clarke L, Boudes P et al (2001) TSE-424, a novel tissue selective estrogen, reduce biochemical indices of bone metabolism in a dose related fashion. J Bone Miner Res 16(S1):S413","journal-title":"J Bone Miner Res"},{"key":"1586_CR51","first-page":"S97","volume":"14","author":"X Ling","year":"2003","unstructured":"Ling X, Jianli L, Jingfang L et al (2003) Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on biochemical markers of bone metabolism in a Chinese population. Osteoporos Int 14:S97\u2013S98","journal-title":"Osteoporos Int"},{"key":"1586_CR52","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","volume":"23","author":"PD Miller","year":"2008","unstructured":"Miller PD, Chines AA, Christiansen C et al (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo, and active-controlled study. J Bone Miner Res 23:525\u2013535","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1586_CR53","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/gme.0b013e3181a816be","volume":"16","author":"JV Pinkerton","year":"2009","unstructured":"Pinkerton JV, Archer DF, Utian WH et al (2009) Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 16(6):1102\u20131108","journal-title":"Menopause"},{"issue":"S1","key":"1586_CR54","first-page":"S174","volume":"20","author":"SY Smith","year":"2005","unstructured":"Smith SY, Minck D, Jolette J et al (2005) Bazedoxifene prevents ovariectomy-induced bone loss in the cynomolgus monkey. J Bone Miner Res 20(S1):S174","journal-title":"J Bone Miner Res"},{"key":"1586_CR55","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1210\/en.2003-1481","volume":"145","author":"HZ Ke","year":"2004","unstructured":"Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD (2004) Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145:1996\u20132005","journal-title":"Endocrinology"},{"key":"1586_CR56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/01.gme.0000227337.73738.c9","volume":"13","author":"XN Wang","year":"2006","unstructured":"Wang XN, Simmons HA, Salatto CT, Cosgrove PG, Thompson DD (2006) Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Menopause 13:609\u2013620","journal-title":"Menopause"},{"key":"1586_CR57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","volume":"13","author":"MR McClung","year":"2006","unstructured":"McClung MR, Siris E, Cummings S et al (2006) Prevention of bone loss in postmenopausal women treated with lasofoxofene compared with raloxifene. Menopause 13:377\u2013386","journal-title":"Menopause"},{"key":"1586_CR58","first-page":"81","volume":"23","author":"SR Cummings","year":"2008","unstructured":"Cummings SR, Eastell R, Ensrud K et al (2008) The effects of lasofoxifene on fractures, breast cancer: 3-year results from the PEARL Trial. J Bone Miner Res 23:81","journal-title":"J Bone Miner Res"},{"key":"1586_CR59","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/en.141.2.809","volume":"141","author":"Q Qu","year":"2000","unstructured":"Qu Q, Zheng H, Dahllund J et al (2000) Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 141:809\u2013820","journal-title":"Endocrinology"},{"key":"1586_CR60","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590410001672197","volume":"18","author":"J Komi","year":"2004","unstructured":"Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O (2004) Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 18:152\u2013158","journal-title":"Gynecol Endocrinol"},{"key":"1586_CR61","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","volume":"24","author":"J Komi","year":"2006","unstructured":"Komi J, Lankinen KS, DeGregorio M et al (2006) Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 24:314\u2013318","journal-title":"J Bone Miner Metab"},{"key":"1586_CR62","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1200\/JCO.2006.09.5992","volume":"25","author":"V Deshmane","year":"2007","unstructured":"Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU (2007) Phase III double-blind trial of arzoxifene compared with tamoxifene for locally advanced or metastatic breast cancer. J Clin Oncol 25:4967\u20134973","journal-title":"J Clin Oncol"},{"key":"1586_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)37755-9","volume":"287","author":"M Sato","year":"1998","unstructured":"Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU (1998) LY353381.HCI: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287:1\u20137","journal-title":"J Pharmacol Exp Ther"},{"key":"1586_CR64","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1359\/jbmr.2002.17.12.2256","volume":"17","author":"YL Ma","year":"2002","unstructured":"Ma YL, Bryant HU, Zeng Q et al (2002) Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 17:2256\u20132264","journal-title":"J Bone Miner Res"},{"key":"1586_CR65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-0-387-72009-8_18","volume":"602","author":"M Stolina","year":"2007","unstructured":"Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ (2007) RANKL inhibition: from mice to men (and women). Adv Exp Med Biol 602:143\u2013150","journal-title":"Adv Exp Med Biol"},{"key":"1586_CR66","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2007","unstructured":"Kearns AE, Khosla S, Kostenuik PJ (2007) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155\u2013192","journal-title":"Endocr Rev"},{"key":"1586_CR67","doi-asserted-by":"crossref","unstructured":"Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165\u2013176","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"1586_CR68","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"EM Lewiecki","year":"2007","unstructured":"Lewiecki EM, Miller PD, McClung MR et al (2007) Two-year treatment with densumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832\u20131841","journal-title":"J Bone Miner Res"},{"key":"1586_CR69","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewieki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229","journal-title":"Bone"},{"key":"1586_CR70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"1586_CR71","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00198-009-0914-1","volume":"20","author":"S Cummings","year":"2009","unstructured":"Cummings S, Zanchetta J, McClung M et al (2009) The effects of twice-yearly denosumab on fracture risk in women with osteoporosis. Osteoporos Int 20:516","journal-title":"Osteoporos Int"},{"key":"1586_CR72","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Eng J Med 354:821\u2013831","journal-title":"N Eng J Med"},{"key":"1586_CR73","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"S Cummings","year":"2009","unstructured":"Cummings S, San Martin J, McClung M et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med 361:756\u2013765","journal-title":"N Eng J Med"},{"key":"1586_CR74","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875\u20134882","journal-title":"J Clin Oncol"},{"issue":"8","key":"1586_CR75","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Toriz NH et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Eng J Med 361(8):745\u2013755","journal-title":"N Eng J Med"},{"key":"1586_CR76","first-page":"CD005326","volume":"18","author":"S O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell S, Cranney A, Wells GA et al (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 18:CD005326","journal-title":"Cochrane Database Syst Rev"},{"key":"1586_CR77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1359\/jbmr.071105","volume":"23","author":"E Seeman","year":"2008","unstructured":"Seeman E, Devogelaer J, Lorenc R et al (2008) Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23:433\u2013438","journal-title":"J Bone Miner Res"},{"key":"1586_CR78","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jocd.2007.03.102","volume":"10","author":"GM Blake","year":"2007","unstructured":"Blake GM, Fogelman I (2007) The correction of BMD measurements for bone strontium content. J Clin Densitometr 10:259\u2013265","journal-title":"J Clin Densitometr"},{"key":"1586_CR79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bone.2007.08.043","volume":"42","author":"E Bonnelye","year":"2008","unstructured":"Bonnelye E, Chabadel A, Saltel F et al (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129\u2013138","journal-title":"Bone"},{"key":"1586_CR80","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbrc.2007.01.120","volume":"355","author":"LL Zhu","year":"2007","unstructured":"Zhu LL, Zaidi S, Peng Y et al (2007) Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophys Res Commun 355:307\u2013311","journal-title":"Biochem Biophys Res Commun"},{"key":"1586_CR81","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bcp.2007.04.020","volume":"74","author":"N Chattopadhyay","year":"2007","unstructured":"Chattopadhyay N, Quinn SJ, Kifor O et al (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate induced osteoblast proliferation. Biochem Pharmacol 74:438\u2013447","journal-title":"Biochem Pharmacol"},{"key":"1586_CR82","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1359\/jbmr.070607","volume":"22","author":"P Ammann","year":"2007","unstructured":"Ammann P, Badoud I, Barraud S et al (2007) Strontium ranelate treatment improves trabecular and cortical intrinsic boe tissue quality, a determinant of bone strength. J Bone Miner Res 22:1419\u20131425","journal-title":"J Bone Miner Res"},{"key":"1586_CR83","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1359\/jbmr.070321","volume":"22","author":"S Choudhary","year":"2007","unstructured":"Choudhary S, Halbout P, Alander C et al (2007) Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J Bone Miner Res 22:1002\u20131010","journal-title":"J Bone Miner Res"},{"key":"1586_CR84","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1210\/jc.2006-2758","volume":"92","author":"O Bruyere","year":"2007","unstructured":"Bruyere O, Roux C, Detilleux J et al (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076\u20133081","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR85","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.060101","volume":"21","author":"C Roux","year":"2006","unstructured":"Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536\u2013542","journal-title":"J Bone Miner Res"},{"key":"1586_CR86","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR87","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Eng J Med 350:459\u2013468","journal-title":"New Eng J Med"},{"key":"1586_CR88","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1210\/jc.87.5.2060","volume":"87","author":"PJ Meunier","year":"2002","unstructured":"Meunier PJ, Slosman DO, Delmas PD et al (2002) Strontium ranelate: dosedependent effects in established postmenopausal vertebral osteoporosis\u2014a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060\u20132066","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR89","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s001980200129","volume":"13","author":"JY Reginster","year":"2002","unstructured":"Reginster JY, Deroisy R, Dougados M et al (2002) Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, doublemasked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 13:925\u2013931","journal-title":"Osteoporos Int"},{"key":"1586_CR90","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.060404","volume":"21","author":"E Seeman","year":"2006","unstructured":"Seeman E, Vellas B, Benhamou C et al (2006) Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21:1113\u20131120","journal-title":"J Bone Miner Res"},{"key":"1586_CR91","unstructured":"http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Protelos\/PressRelease_Protelos_41745807en.pdf"},{"key":"1586_CR92","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11914-008-0025-5","volume":"6","author":"M Shahnazari","year":"2008","unstructured":"Shahnazari M, Yao W, Corr M, Lane NE (2008) Targeting the Wnt signaling pathway to augment bone formation. Curr Osteoporos Rep 6:142\u2013148","journal-title":"Curr Osteoporos Rep"},{"key":"1586_CR93","first-page":"354","volume":"6","author":"AG Robling","year":"2006","unstructured":"Robling AG, Bellido T, Turner CH (2006) Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 6:354","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"1586_CR94","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","volume":"283","author":"AG Robling","year":"2007","unstructured":"Robling AG, Niziolek PJ, Baldridge LA et al (2007) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin. J Biol Chem 283:5866\u20135875","journal-title":"J Biol Chem"},{"key":"1586_CR95","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","volume":"35","author":"MK Sutherland","year":"2004","unstructured":"Sutherland MK, Geoghegan JC, Yu C et al (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35:828\u2013835","journal-title":"Bone"},{"key":"1586_CR96","doi-asserted-by":"crossref","first-page":"36293","DOI":"10.1074\/jbc.M400521200","volume":"279","author":"DG Winkler","year":"2004","unstructured":"Winkler DG, Yu C, Geoghegan JC et al (2004) Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 279:36293\u201336298","journal-title":"J Biol Chem"},{"key":"1586_CR97","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1359\/jbmr.070804","volume":"22","author":"O Leupin","year":"2007","unstructured":"Leupin O, Kramer I, Collette NM et al (2007) Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22:1957\u20131967","journal-title":"J Bone Miner Res"},{"key":"1586_CR98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10735-007-9158-6","volume":"39","author":"G Silvestrini","year":"2008","unstructured":"Silvestrini G, Ballanti P, Sebastiani M et al (2008) OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST. J Mol Histol 39:237\u2013242","journal-title":"J Mol Histol"},{"issue":"8 Suppl","key":"1586_CR99","first-page":"15","volume":"28","author":"RL Bezooijen Van","year":"2005","unstructured":"Van Bezooijen RL, Papapoulos SE, L\u00f6wik CW (2005) Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest 28(8 Suppl):15\u201317","journal-title":"J Endocrinol Invest"},{"key":"1586_CR100","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li X, Ominsky MS, Niu QT et al (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860\u2013869","journal-title":"J Bone Miner Res"},{"key":"1586_CR101","doi-asserted-by":"crossref","unstructured":"Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone; PMID: 20561907","DOI":"10.1016\/j.bone.2010.05.032"},{"issue":"5","key":"1586_CR102","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky MS, Vlasseros F, Jolette J et al (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density and bone strength. J Bone Miner Res 25(5):948\u2013959","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1586_CR103","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","volume":"24","author":"X Li","year":"2009","unstructured":"Li X, Ominsky MS, Warmington KS, Morony S et al (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578\u2013588","journal-title":"J Bone Miner Res"},{"key":"1586_CR104","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11914-010-0005-4","volume":"8","author":"NE Lane","year":"2010","unstructured":"Lane NE, Silverman SL (2010) Anabolic therapies. Curr Osteoporos Rep 8:23\u201327","journal-title":"Curr Osteoporos Rep"},{"key":"1586_CR105","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2008.09.059","volume":"135","author":"VK Yadav","year":"2008","unstructured":"Yadav VK, Ryu JH, Suda N et al (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825\u2013837","journal-title":"Cell"},{"key":"1586_CR106","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","volume":"273","author":"BD Gelb","year":"1996","unstructured":"Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236\u20131238","journal-title":"Science"},{"key":"1586_CR107","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1359\/jbmr.2001.16.8.1444","volume":"16","author":"R Kiviranta","year":"2001","unstructured":"Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J (2001) Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 16:1444\u20131452","journal-title":"J Bone Miner Res"},{"key":"1586_CR108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2004.09.020","volume":"36","author":"R Kiviranta","year":"2005","unstructured":"Kiviranta R, Morko J, Alatalo SL et al (2005) Impaired bone resorption in cathepsin K deficient mice is partially compensated by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL\/OPG ratio. Bone 36:159\u2013172","journal-title":"Bone"},{"key":"1586_CR109","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.bone.2005.02.006","volume":"36","author":"J Morko","year":"2005","unstructured":"Morko J, Kiviranta R, Hurme S, Rantakokko J, Vuorio E (2005) Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K. Bone 36:854\u2013865","journal-title":"Bone"},{"key":"1586_CR110","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1359\/jbmr.1999.14.11.1934","volume":"14","author":"J Rantakokko","year":"1999","unstructured":"Rantakokko J, Uusitalo H, Jamsa T, Tuukkanen J, Aro HT, Vuorio E (1999) Expression profiles of mRNAs for osteoblast and osteoclast proteins as indicators of bone loss in mouse immobilization osteopenia model. J Bone Miner Res 14:1934\u20131942","journal-title":"J Bone Miner Res"},{"key":"1586_CR111","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lab.2005.03.016","volume":"146","author":"G Holzer","year":"2005","unstructured":"Holzer G, Noske H, Lang T, Holzer L, Willinger U (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146:13\u201317","journal-title":"J Lab Clin Med"},{"key":"1586_CR112","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","volume":"42","author":"K Fuller","year":"2008","unstructured":"Fuller K, Lawrence KM, Ross JL et al (2008) Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 42:200\u2013211","journal-title":"Bone"},{"issue":"3","key":"1586_CR113","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","volume":"18","author":"JY Gauthier","year":"2008","unstructured":"Gauthier JY, Chauret N, Cromlish W et al (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18(3):923\u2013928","journal-title":"Bioorg Med Chem Lett"},{"key":"1586_CR114","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1359\/jbmr.060715","volume":"21","author":"S Adami","year":"2006","unstructured":"Adami S, Supronik J, Hala T et al (2006) Effect of one year treatment with the cathepsin-k inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteoporosis\/osteopenia. J Bone Miner Res 21:S24","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1586_CR115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","volume":"25","author":"HG Bone","year":"2010","unstructured":"Bone HG, McClung MR, Roux C et al (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two year study in postmenopausal women with low bone density. J Bone Miner Res 25(5):937\u2013947","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1586_CR116","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2009.60","volume":"86","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, Zajic S, Stone J et al (2009) Effect of cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy ostmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86(2):175\u2013182","journal-title":"Clin Pharmacol Ther"},{"key":"1586_CR117","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S8756-3282(97)00014-8","volume":"20","author":"AJ Millest","year":"1997","unstructured":"Millest AJ, Breen SA, Loveday BE et al (1997) Effects of an inhibitor of cathepsin l on bone resorption in thyroparathyroidectomized and ovariectomized rats. Bone 20:465\u2013471","journal-title":"Bone"},{"key":"1586_CR118","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.0959-9673.2004.00373.x","volume":"85","author":"W Potts","year":"2004","unstructured":"Potts W, Bowyer J, Jones H et al (2004) Cathepsin l deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol 85:85\u201396","journal-title":"Int J Exp Pathol"},{"key":"1586_CR119","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0009-8981(99)00230-2","volume":"291","author":"JM Delaisse","year":"2000","unstructured":"Delaisse JM, Engsig MT, Everts V et al (2000) Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta 291:223\u2013234","journal-title":"Clin Chim Acta"},{"key":"1586_CR120","first-page":"237","volume":"39","author":"JC Fernandes","year":"2002","unstructured":"Fernandes JC, Martel-Pelletier J, Pelletier JP (2002) The role of cytokines in osteoarthritis pathology. Biorheology 39:237\u2013246","journal-title":"Biorheology"},{"key":"1586_CR121","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MCO.0b013e32832a3d79","volume":"12","author":"S Bhasin","year":"2009","unstructured":"Bhasin S, Jasuja R (2009) Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 12:232\u2013240","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"1586_CR122","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1210\/en.2005-0572","volume":"146","author":"W Gao","year":"2005","unstructured":"Gao W, Reiser PJ, Coss CC et al (2005) Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinol 146:4887\u20134897","journal-title":"Endocrinol"},{"key":"1586_CR123","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11095-006-9152-9","volume":"24","author":"JD Kearbey","year":"2007","unstructured":"Kearbey JD, Gao W, Narayanan R et al (2007) Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 24:328\u2013335","journal-title":"Pharm Res"},{"key":"1586_CR124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12033-007-0072-7","volume":"38","author":"SA Mousa","year":"2008","unstructured":"Mousa SA (2008) Cell adhesion molecules: potential therapeutic and diagnostic implications. Mol Biotechnol 38:33\u201340","journal-title":"Mol Biotechnol"},{"key":"1586_CR125","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(94)90007-8","volume":"79","author":"PC Brooks","year":"1994","unstructured":"Brooks PC, Montgomery AMP, Rosenfield M et al (1994) Integrin xv\u03b23 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157\u20131164","journal-title":"Cell"},{"key":"1586_CR126","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1357-2725(96)00155-0","volume":"29","author":"MA Horton","year":"1997","unstructured":"Horton MA (1997) The \u03b1v\u03b23 integrins \u201cvitronectin receptor\u201d. Int J Biochem Cell Biol 29:721\u2013725","journal-title":"Int J Biochem Cell Biol"},{"key":"1586_CR127","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-007-0773-9","volume":"25","author":"I Nakamura","year":"2007","unstructured":"Nakamura I, Duong LT, Rodan SB, Rodan G (2007) Involvement of \u03b1v\u03b23 integrins in osteoclast function. J Bone Miner Metab 25:337\u2013344","journal-title":"J Bone Miner Metab"},{"key":"1586_CR128","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/jc.2004-2126","volume":"90","author":"MG Murphy","year":"2005","unstructured":"Murphy MG, Cerchio K, Stoch SA et al (2005) Effect of l-000845704, an alphavbeta3, integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 90:2022\u20132028","journal-title":"J Clin Endocrinol Metab"},{"key":"1586_CR129","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00223-004-0147-4","volume":"76","author":"S Colucci","year":"2005","unstructured":"Colucci S, Mori G, Vaira S et al (2005) l-carnitine and isovaleryl l-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 76:458\u2013465","journal-title":"Calcif Tissue Int"},{"key":"1586_CR130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00223-008-9109-6","volume":"82","author":"N Patano","year":"2008","unstructured":"Patano N, Mancini L, Settanni MP et al (2008) l-carnitine fumarate and isovaleryl-l-carnitine fumarate accelerate the recovery of bone volume\/total volume ratio after experimentally induced osteoporosis in pregnant mice. Calcif Tissue Int 82:221\u2013228","journal-title":"Calcif Tissue Int"},{"key":"1586_CR131","first-page":"15","volume":"2","author":"J Cornish","year":"2001","unstructured":"Cornish J, Reid IR (2001) Effects of amylin and adrenomedullin on the skeleton. J Musculoskel Neuron Interact 2:15\u201324","journal-title":"J Musculoskel Neuron Interact"},{"key":"1586_CR132","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bbrc.1995.1163","volume":"207","author":"J Cornish","year":"1995","unstructured":"Cornish J, Callon KE, Cooper GJS, Reid IR (1995) Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun 207:133\u2013139","journal-title":"Biochem Biophys Res Commun"},{"key":"1586_CR133","doi-asserted-by":"crossref","first-page":"E694","DOI":"10.1152\/ajpendo.1998.275.4.E694","volume":"38","author":"J Cornish","year":"1998","unstructured":"Cornish J, Callon KE, King AR, Cooper GJS, Reid IR (1998) Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Ame J Physiol-Endocrinol Metab 38:E694\u2013E699","journal-title":"Ame J Physiol-Endocrinol Metab"},{"key":"1586_CR134","doi-asserted-by":"crossref","first-page":"E1113","DOI":"10.1152\/ajpendo.1997.273.6.E1113","volume":"273","author":"J Cornish","year":"1997","unstructured":"Cornish J, Callon KE, Coy DH et al (1997) Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. Am J Physiol-Endocrinol Metab 273:E1113\u2013E1120","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"1586_CR135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1677\/joe.0.1700251","volume":"170","author":"J Cornish","year":"2001","unstructured":"Cornish J, Callon KE, Bava U et al (2001) Systemic administration of adrenomedullin (27\u201352) increases bone volume and strength in male mice. J Endocrinol 170:251\u2013257","journal-title":"J Endocrinol"},{"key":"1586_CR136","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1210\/en.142.5.1849","volume":"142","author":"D Naot","year":"2001","unstructured":"Naot D, Callon KE, Cooper GJS, Reid IR, Cornish J (2001) A potential role for adrenomedullin as a local regulator of bone growth. Endocrinol 142:1849\u20131857","journal-title":"Endocrinol"},{"key":"1586_CR137","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/en.138.1.440","volume":"138","author":"LM Montuenga","year":"1997","unstructured":"Montuenga LM, Martinez A, Miller MJ, Unsworth EJ, Cuttitta F (1997) Expression of adrenomedullin and its receptor during embryogenesis suggests autocrine or paracrine modes of action. Endocrinol 138:440\u2013451","journal-title":"Endocrinol"},{"issue":"3","key":"1586_CR138","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00198-003-1538-5","volume":"15","author":"J Bronsky","year":"2004","unstructured":"Bronsky J, Pr\u016fsa R (2004) Amylin fasting plasma levels are decreased in patients with osteoporosis. Osteoporos Int 15(3):243\u2013247","journal-title":"Osteoporos Int"},{"issue":"1","key":"1586_CR139","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jcp.21294","volume":"215","author":"B Uzan","year":"2008","unstructured":"Uzan B, Villemin A, Garel JM, Cressent M (2008) Adrenomodulin is anti-apoptotic in osteoblasts through CGRP1 receptors and MEK-ERK pathway. J Cell Physiol 215(1):122\u2013128","journal-title":"J Cell Physiol"},{"key":"1586_CR140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1210\/er.19.1.55","volume":"19","author":"C Ohlsson","year":"1998","unstructured":"Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC (1998) Growth hormone and bone. Endocr Rev 19:55\u201379","journal-title":"Endocr Rev"},{"key":"1586_CR141","first-page":"59","volume":"75","author":"JP Liu","year":"1993","unstructured":"Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and type 1 IGF receptor (IGF1r). Cell 75:59\u201372","journal-title":"Cell"},{"key":"1586_CR142","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1359\/jbmr.2001.16.12.2320","volume":"16","author":"D Bikle","year":"2001","unstructured":"Bikle D, Majumdar S, Laib A et al (2001) The skeletal structure of insulin-like growth factor I-deficient mice. J Bone Miner Res 16:2320\u20132329","journal-title":"J Bone Miner Res"},{"key":"1586_CR143","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1359\/jbmr.060618","volume":"21","author":"JL Fowlkes","year":"2006","unstructured":"Fowlkes JL, Thrailkill KM, Liu L et al (2006) Effects of systemic and local administration of recombinant human IGF-I (rjIGF-I) on de novo bone formation in an aged mouse model. J Bone Miner Res 21:1359\u20131366","journal-title":"J Bone Miner Res"},{"key":"1586_CR144","doi-asserted-by":"crossref","unstructured":"Kanazawa I, Yamaguchi T, Sugimoto T (2010) Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. doi: 10.1007\/s00198-010-1310-6 [Epub ahead of print]","DOI":"10.1007\/s00198-010-1310-6"},{"issue":"1","key":"1586_CR145","first-page":"64","volume":"10","author":"MW Hamrick","year":"2010","unstructured":"Hamrick MW, McNeil PL, Patterson SL (2010) Role of muscle-derived growth factors in bone formation. J Musculoskelet Neuronal Interact 10(1):64\u201370","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"1586_CR146","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1073\/pnas.0505663103","volume":"103","author":"JT Woo","year":"2006","unstructured":"Woo JT, Kawatani M, Kato M et al (2006) Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci USA 103:4729\u20134734","journal-title":"Proc Natl Acad Sci USA"},{"key":"1586_CR147","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1254\/jphs.FM0070288","volume":"106","author":"JT Woo","year":"2008","unstructured":"Woo JT, Yonezawa T, Cha BY, Teruya T, Nagai K (2008) Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation function and survival. J Pharmacol Sci 106:547\u2013554","journal-title":"J Pharmacol Sci"},{"issue":"24","key":"1586_CR148","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1158\/1078-0432.CCR-05-1335","volume":"11","author":"H Muguruma","year":"2005","unstructured":"Muguruma H, Yano S, Kakiuchi S et al (2005) Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity. Clin Cancer Res 11(24):8822\u20138828","journal-title":"Clin Cancer Res"},{"key":"1586_CR149","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MOT.0b013e328333d52c","volume":"15","author":"GA Clines","year":"2010","unstructured":"Clines GA (2010) Prospects for osteoprogenitor stem cells in fracture repair and osteoporosis. Curr Opin Organ Transplant 15:73\u201378","journal-title":"Curr Opin Organ Transplant"},{"key":"1586_CR150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM200102013440516","volume":"344","author":"R Quarto","year":"2001","unstructured":"Quarto R, Mastrogiacomo M, Cancedda R et al (2001) Repair of large bone defects with the use of autologous bne marrow stromal cells. N Eng J Med 344:385\u2013386","journal-title":"N Eng J Med"},{"key":"1586_CR151","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1073\/pnas.132252399","volume":"99","author":"EM Horwitz","year":"2002","unstructured":"Horwitz EM, Gordon PL, Koo WK et al (2002) Isolated allogenic bone marrow derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfect: implications for cell therapy of bone. Proc Natl Acad Sci USA 99:8932\u20138937","journal-title":"Proc Natl Acad Sci USA"},{"key":"1586_CR152","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.cellbi.2008.06.005","volume":"32","author":"Y Tang","year":"2008","unstructured":"Tang Y, Tang W, Lin Y et al (2008) Combination of bone tissue engineering and BMP-2 gene transfection promotes bone healing in osteoporotic rats. Cell Biol Int 32:1150\u20131157","journal-title":"Cell Biol Int"},{"key":"1586_CR153","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","volume":"79","author":"P Tontonoz","year":"1994","unstructured":"Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147\u20131156","journal-title":"Cell"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-010-1586-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-010-1586-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-010-1586-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T15:36:07Z","timestamp":1740324967000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-010-1586-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,30]]},"references-count":153,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["1586"],"URL":"https:\/\/doi.org\/10.1007\/s00296-010-1586-z","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,30]]}}}